GLP-1 receptor agonists (GLP-1RAs), novel agents that are dual and triple hormonal agonists, have emerged as valuable therapeutic agents for managing obesity and type 2 diabetes [1]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.